Xeltis Expands Medical Advisory Board with Leading Nephrology Experts
Xeltis, an innovative developer of transformative implants designed to facilitate the natural creation of living and long-lasting vessels, is thrilled to announce the inclusion of renowned clinical nephrology experts An De Vriese, MD, PhD, and Monnie Wasse, MD, MPH, to its Medical Advisory Board (MAB). Their appointment is a significant step forward in Xeltis' clinical journey towards enhancing patient care and advancing treatment options in nephrology.
Significant Contributions from Nephrology Experts
Dr. An De Vriese is currently leading the Division of Nephrology and Infectious Disease at AZ Sint-Jan Brugge, while also serving as a Guest Professor at Ghent University. Dr. Monnie Wasse holds the position of Interim Chair of Internal Medicine and is also the Chief of Nephrology and Director of Interventional Nephrology at Rush University Medical Center. Their extensive backgrounds bring invaluable expertise to Xeltis, enhancing the existing advisory team and supporting the company’s strategic and clinical efforts.
Statements from Company Leadership
Eliane Schutte, the Chief Executive Officer of Xeltis, expressed her enthusiasm about the new appointments, stating, "We are pleased that both An and Monnie have chosen to join our Medical Advisory Board, bolstering our already stellar team of advisors. The appointments represent significant validation of the unique and promising nature of our technology from leading experts in the field. Their experience in nephrology and vascular access will be invaluable as we continue to progress aXess through its pivotal trials in various regions, with primary readouts for our pivotal trial expected soon."
An Innovative Approach to Nephrology
Dr. An De Vriese shared her thoughts on joining the advisory board, stating, "It is an honor to join Xeltis' MAB at such a pivotal time in the Company's development. I am truly excited by Xeltis' innovative technology which aims to avoid complications like frequent re-interventions and infections that are common with current treatment options. This has the potential to greatly improve outcomes for patients suffering from end-stage renal disease."
Commitment to Advancing Clinical Development
Dr. Monnie Wasse affirmed her commitment to the company's vision, remarking, "I have followed the impactful work of Xeltis closely and am impressed by the continuous clinical advancements of its technologies. aXess has a highly promising medical profile, and I am glad to contribute my expertise in interventional nephrology and vascular access to further enhance the clinical development of this groundbreaking technology."
About aXess and Clinical Trials
aXess is a restorative vascular access conduit designed for creating new, long-term living vessels for hemodialysis. This innovative solution combines the advantageous aspects of traditional fistulas and AV grafts while minimizing complications and easing the frequency of interventions. Currently, Xeltis is conducting pivotal trials across international markets, recently completing patient enrollment in Europe and marking significant milestones in patient implantation in the United States, demonstrating robust clinical progress.
Company Overview: Innovating Nephrology Treatments
Xeltis operates with the mission of developing transformative medical technologies that empower the creation of living, durable vessels for patients requiring hemodialysis grafts and cardiovascular solutions. Their proprietary endogenous tissue restoration (ETR) platform uses advanced polymers for implantable devices that foster the regeneration of patient tissue. This approach aims to deliver solutions for essential healthcare challenges faced by patients worldwide.
Significant Impacts on Healthcare
The aXess technology stands at the forefront of Xeltis’ innovation efforts, demonstrating remarkable potential in addressing the limitations seen with existing grafts and vascular replacements. Xeltis’ impressive trajectory invites attention to its solutions that enhance patient outcomes and satisfaction.
About Our New Advisory Board Members
Dr. An De Vriese has dedicated her career to research in clinical nephrology, holding a remarkable track record of achievement, including a Ph.D. in Medical Science and over 180 contributions to medical literature. Her role at Xeltis strengthens the clinical understanding and guidance within the advisory board.
Profound Influence in the Field
Similarly, Dr. Monnie Wasse brings profound expertise as an Interventional Nephrologist, occupying significant leadership positions and conducting impactful research in the field of dialysis vascular access. Her prior achievements serve as a testament to her ability to influence nephrology care on both a national and international scale.
Frequently Asked Questions
1. What is the purpose of Xeltis' Medical Advisory Board?
The Medical Advisory Board provides strategic and clinical guidance to Xeltis as it develops its technologies and advances clinical trials.
2. Who are the new members of the Medical Advisory Board?
The new members are Dr. An De Vriese and Dr. Monnie Wasse, both of whom are recognized leaders in nephrology.
3. What is the aXess technology?
aXess is a restorative vascular access conduit aimed at creating new, long-term living vessels for hemodialysis, improving patient outcomes.
4. Where is Xeltis based?
Xeltis operates out of The Netherlands and the USA, focusing on innovative solutions for healthcare challenges.
5. How does Xeltis' technology aim to improve patient care?
Xeltis' technology aims to reduce complications associated with current treatment options, thus enhancing patient outcomes for those requiring vascular access.
